Paik, Jong-Woo

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 308

The effects of continuous antidepressant treatment during the first 6months on relapse or recurrence of depression

Kim, K.-H., Lee, S.-M., Paik, J.-W., & Kim, N.-S. (2011) · Journal of Affective Disorders

Treatment of Major DepressionMental Health Treatment and Access

Cited by 34

Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study

Wajs, E., Leah, A., Morrison, R., Daly, E., Lane, R., Lim, P., Holder, R., Sanacora, G., Young, A. H., Kasper, S., et al. (2019) · European Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 19